Carolyne Zimmermann joins 4D Molecular Therapeutics as Chief Business Officer. Ms. Zimmermann brings nearly 20 years of leadership experience in life sciences corporate and business development from her prior roles at Johnson & Johnson and Novartis Pharmaceuticals.
Ms. Zimmermann joins 4DMT from Johnson & Johnson Innovation where she served as Vice President, Transactions. In this role, she led the transaction team on all deal-related matters, including sourcing and executing transactions as well as supporting J&J’s Lung Cancer Initiative’s early innovation deal making efforts. Prior to that, she spent over 13 years in leadership roles within the Global Business Development & Licensing group at Novartis Pharmaceuticals, where she gained extensive experience in structuring and negotiating strategic transactions with both pharmaceutical and biotechnology entities, including collaborations, licensing deals, acquisitions, and equity investments. At Novartis, she led the Global Cardio-Metabolic Franchise’s Business Development and Licensing efforts, where she was responsible for driving the external strategy and securing strategic assets to expand the portfolio. Additionally, she was also a General Partner at dRx Capital, a $100mn venture fund founded in 2015 by Novartis and Qualcomm Ventures focused on early-stage digital health investing.
Carolyne earned her B.S. in Engineering Sciences from the University of California, San Diego and her M.B.A. from Columbia Business School in New York.